H.B. Fuller Successfully Executes 13 Acquisitions in 2023
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 26 2026
0mins
"Our Board and management team value the feedback of all shareholders and regularly engage with and listen to a diverse range of perspectives shared with the Company, as we have with Ancora. The H.B. Fuller management team is successfully executing on our stated strategy to reposition the business into a faster-growing and higher margin specialty adhesives player. Our team's strong operational execution combined with a disciplined M&A strategy are how we will achieve our goals of greater than 20% adjusted EBITDA margins, low-teens ROIC and strong cash flow conversion. H.B. Fuller has a demonstrated track record of thoughtful and disciplined M&A. We operate in a highly fragmented market, which enables us to prudently acquire assets that enhance our scale, accelerate our evolution to higher growth and position us to quickly de-lever post-acquisition. Since the beginning of 2023, H.B. Fuller has successfully executed 13 acquisitions, which, collectively, have resulted in significant adjusted EBITDA growth and margin expansion through synergy capture, as outlined during our October 2025 Investor Day. For example, in the U.K. alone, we have acquired four businesses since 2022, representing $30 million of acquired adjusted EBITDA with approximately 13% adjusted EBITDA margins. Through delivery of synergies, we have collectively grown those businesses to more than $60 million in adjusted EBITDA with more than 23% adjusted EBITDA margins in three years. We have pursued this M&A strategy while balancing other capital allocation priorities. To that end, we have been methodically deleveraging our balance sheet over the past several years, including reducing our net debt to adjusted EBITDA ratio to 3.1x at the end of the first quarter versus 3.5x in the same period last year. H.B. Fuller remains open to assessing any and all paths to value creation and we are committed to both extremely disciplined M&A and deleveraging. Our recent disclosure regarding Advanced Medical Solutions Group plc ("AMS") was required by the U.K. Takeover Code. We are engaged in discussions with AMS but there can be no certainty that a binding offer will be made. We will evaluate this transaction with the same rigor and care that we have applied to all of the other transactions that we have considered. We look forward to continued constructive conversations with our shareholders regarding our strategy and opportunities for value creation."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FUL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FUL
Wall Street analysts forecast FUL stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 63.600
Low
60.00
Averages
70.00
High
80.00
Current: 63.600
Low
60.00
Averages
70.00
High
80.00
About FUL
H.B. Fuller Company is a pureplay adhesives company. It operates as a formulator, manufacturer and marketer of adhesives, sealants and other specialty chemical products. Its Hygiene, Health and Consumable Adhesives segment manufactures and supplies adhesive products in the assembly, packaging, converting, nonwoven and hygiene, health and beauty, graphic arts and envelope markets. Its Engineering Adhesives segment produces and supplies industrial adhesives, such as reactive, light cure, two-part liquids, polyurethane, silicone, film and fast cure products. The Building Adhesive Solutions segment includes products used for the commercial roofing industry (pressure-sensitive adhesives, tapes and sealants) and heating, ventilation and air conditioning and insulation applications (duct sealants, weather barriers and fungicidal coatings and block fillers). It also includes caulks and sealants for the consumer market and professional trade, sold through retailers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
H.B. Fuller Invests in Advanced Oxygen Barrier Technology
- Strategic Investment: H.B. Fuller announces a strategic investment in VerdaFresh, enhancing its barrier coating offerings and accelerating the shift towards fully recyclable packaging, which is expected to significantly boost market competitiveness.
- Material Optimization: VerdaFresh's proprietary technology integrates directly into H.B. Fuller's barrier coatings, eliminating reliance on EVOH and other hard-to-recycle materials, thereby reducing overall material use and lowering environmental footprint.
- Economic and Environmental Benefits: The new technology not only enhances recyclability but also streamlines structures and reduces dependence on costly multi-layer materials, helping customers achieve both environmental and economic benefits simultaneously.
- Market Leadership: This new capability positions H.B. Fuller to lead the transition towards circular, high-performance packaging, meeting rising regulatory and consumer expectations without compromising on product shelf life and protection.
See More
FUL Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: FUL's 52-week low is $48.71 per share, while the high is $68.63, with the last trade at $60.80, indicating significant price movement within this range and reflecting market attention and investor sentiment changes.
- Technical Indicator Observation: Currently, FUL's stock price is positioned in the middle of its 52-week range, suggesting a neutral market expectation for its future performance, which may influence investor buying decisions, particularly considering its dividend yield.
- Market Trend Impact: The stock's price movement is related to nine other dividend stocks that recently crossed above their 200-day moving average, indicating a growing market preference for high-dividend stocks, which could enhance FUL's investment appeal.
- Investor Sentiment Assessment: Although the current price is below the 52-week high, it remains above the low, demonstrating a degree of market confidence, prompting investors to closely monitor FUL's performance in future trades to assess its investment value.
See More
Activist Investor Pressures H.B. Fuller to Abandon AMS Acquisition
- Investor Pressure: Activist investor Ancora Holdings, holding over 2% of H.B. Fuller, is urging the company to abandon its proposed acquisition of UK-based Advanced Medical Solutions Group Plc and instead conduct a comprehensive strategic review, including evaluating potential sale options, to avoid further damage to the company's market credibility.
- Acquisition Amount Revealed: H.B. Fuller has reportedly bid over £600 million ($806 million) for AMS, a move that has drawn strong opposition from Ancora, which argues that such a high-priced acquisition could harm the company's value, highlighting investor concerns over management decisions.
- Management Warning: Ancora's CEO Fred DiSanto and President James Chadwick warned in their letter that the Board still has time to halt the acquisition to prevent greater reputational damage among shareholders, emphasizing the responsibility of management in capital allocation decisions.
- Stock Price Reaction: Despite facing investor pressure, H.B. Fuller’s shares rose 1.3% on Tuesday, indicating some market confidence in the company's future performance, although the warnings from investors could impact long-term shareholder value.
See More
Letter Opposing Acquisition of AMS
- Management Commitment Breach: H.B. Fuller management's commitment during the Q1 2026 earnings call to focus on deleveraging is contradicted by the proposed acquisition of AMS, which would push net debt to adjusted EBITDA ratio above 4.0x, potentially eroding investor trust.
- Significant Acquisition Risks: The acquisition of AMS would thrust the company into a new product category where it lacks experience, and the management's insufficient track record in integrating cross-border operations could lead to increased operational risks, further impacting market valuation.
- Strong Shareholder Opposition: Ancora Holdings Group, owning over 2% of H.B. Fuller, vehemently opposes the AMS acquisition, arguing it would damage the company's credibility with investors and urging the board to conduct a comprehensive strategic review.
- Increased Market Valuation Pressure: H.B. Fuller currently trades at a significant discount to its intrinsic value, and pursuing AMS would exacerbate this discount, leading to greater value loss for shareholders, especially given the approximately 25% decline in total shareholder returns during the CEO's tenure.
See More
British Medical Supplier Receives Unsolicited Takeover Proposal
- Takeover Proposal: British medical supplier Advanced Medical Solutions has received an unsolicited takeover proposal from U.S.-based adhesives maker H.B. Fuller, following failed buyout talks with a private equity firm, indicating heightened market interest in its valuation.
- Stock Price Reaction: Following the acquisition news, Advanced Medical Solutions' shares surged by 13.5% to 240 pence, reflecting investor optimism regarding the potential acquisition, which could enhance the company's market valuation.
- Market Dynamics: This takeover proposal comes after unsuccessful negotiations with a private equity firm, highlighting the company's proactive stance in seeking strategic partnerships, which may attract more investor attention to its future prospects.
- Industry Impact: H.B. Fuller's acquisition interest could prompt other industry players to reassess Advanced Medical Solutions' market position, potentially influencing the competitive landscape across the medical supply chain.
See More
H.B. Fuller Establishes Aerospace Manufacturing Center of Excellence
- Strategic Investment: H.B. Fuller has announced the establishment of an Aerospace Manufacturing Center of Excellence in Charlotte, North Carolina, expected to open in early 2027, marking a significant milestone in the company's long-term growth strategy in the aviation, space, and defense markets.
- Project Quantum Leap: This center is part of the company's 'Quantum Leap' initiative aimed at optimizing its global footprint and concentrating resources on high-value, high-margin segments, thereby enhancing overall operational efficiency and market competitiveness.
- Quality and Compliance: The new center will achieve AS9100 certification, ensuring compliance with the most stringent regulatory and quality standards in the aerospace industry, while also planning to pursue Nadcap accreditation to further reinforce customer trust and operational excellence.
- Technology Integration: The facility will consolidate specialized manufacturing, packaging, testing, and quality operations, providing advanced infrastructure and technical expertise to ensure customers achieve consistency and reliability in qualifying new platforms.
See More
H.B. Fuller Invests in Advanced Oxygen Barrier Technology
- Strategic Investment: H.B. Fuller announces a strategic investment in VerdaFresh, enhancing its barrier coating offerings and accelerating the shift towards fully recyclable packaging, which is expected to significantly boost market competitiveness.
- Material Optimization: VerdaFresh's proprietary technology integrates directly into H.B. Fuller's barrier coatings, eliminating reliance on EVOH and other hard-to-recycle materials, thereby reducing overall material use and lowering environmental footprint.
- Economic and Environmental Benefits: The new technology not only enhances recyclability but also streamlines structures and reduces dependence on costly multi-layer materials, helping customers achieve both environmental and economic benefits simultaneously.
- Market Leadership: This new capability positions H.B. Fuller to lead the transition towards circular, high-performance packaging, meeting rising regulatory and consumer expectations without compromising on product shelf life and protection.
See More
FUL Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: FUL's 52-week low is $48.71 per share, while the high is $68.63, with the last trade at $60.80, indicating significant price movement within this range and reflecting market attention and investor sentiment changes.
- Technical Indicator Observation: Currently, FUL's stock price is positioned in the middle of its 52-week range, suggesting a neutral market expectation for its future performance, which may influence investor buying decisions, particularly considering its dividend yield.
- Market Trend Impact: The stock's price movement is related to nine other dividend stocks that recently crossed above their 200-day moving average, indicating a growing market preference for high-dividend stocks, which could enhance FUL's investment appeal.
- Investor Sentiment Assessment: Although the current price is below the 52-week high, it remains above the low, demonstrating a degree of market confidence, prompting investors to closely monitor FUL's performance in future trades to assess its investment value.
See More
Activist Investor Pressures H.B. Fuller to Abandon AMS Acquisition
- Investor Pressure: Activist investor Ancora Holdings, holding over 2% of H.B. Fuller, is urging the company to abandon its proposed acquisition of UK-based Advanced Medical Solutions Group Plc and instead conduct a comprehensive strategic review, including evaluating potential sale options, to avoid further damage to the company's market credibility.
- Acquisition Amount Revealed: H.B. Fuller has reportedly bid over £600 million ($806 million) for AMS, a move that has drawn strong opposition from Ancora, which argues that such a high-priced acquisition could harm the company's value, highlighting investor concerns over management decisions.
- Management Warning: Ancora's CEO Fred DiSanto and President James Chadwick warned in their letter that the Board still has time to halt the acquisition to prevent greater reputational damage among shareholders, emphasizing the responsibility of management in capital allocation decisions.
- Stock Price Reaction: Despite facing investor pressure, H.B. Fuller’s shares rose 1.3% on Tuesday, indicating some market confidence in the company's future performance, although the warnings from investors could impact long-term shareholder value.
See More
Letter Opposing Acquisition of AMS
- Management Commitment Breach: H.B. Fuller management's commitment during the Q1 2026 earnings call to focus on deleveraging is contradicted by the proposed acquisition of AMS, which would push net debt to adjusted EBITDA ratio above 4.0x, potentially eroding investor trust.
- Significant Acquisition Risks: The acquisition of AMS would thrust the company into a new product category where it lacks experience, and the management's insufficient track record in integrating cross-border operations could lead to increased operational risks, further impacting market valuation.
- Strong Shareholder Opposition: Ancora Holdings Group, owning over 2% of H.B. Fuller, vehemently opposes the AMS acquisition, arguing it would damage the company's credibility with investors and urging the board to conduct a comprehensive strategic review.
- Increased Market Valuation Pressure: H.B. Fuller currently trades at a significant discount to its intrinsic value, and pursuing AMS would exacerbate this discount, leading to greater value loss for shareholders, especially given the approximately 25% decline in total shareholder returns during the CEO's tenure.
See More
British Medical Supplier Receives Unsolicited Takeover Proposal
- Takeover Proposal: British medical supplier Advanced Medical Solutions has received an unsolicited takeover proposal from U.S.-based adhesives maker H.B. Fuller, following failed buyout talks with a private equity firm, indicating heightened market interest in its valuation.
- Stock Price Reaction: Following the acquisition news, Advanced Medical Solutions' shares surged by 13.5% to 240 pence, reflecting investor optimism regarding the potential acquisition, which could enhance the company's market valuation.
- Market Dynamics: This takeover proposal comes after unsuccessful negotiations with a private equity firm, highlighting the company's proactive stance in seeking strategic partnerships, which may attract more investor attention to its future prospects.
- Industry Impact: H.B. Fuller's acquisition interest could prompt other industry players to reassess Advanced Medical Solutions' market position, potentially influencing the competitive landscape across the medical supply chain.
See More
H.B. Fuller Establishes Aerospace Manufacturing Center of Excellence
- Strategic Investment: H.B. Fuller has announced the establishment of an Aerospace Manufacturing Center of Excellence in Charlotte, North Carolina, expected to open in early 2027, marking a significant milestone in the company's long-term growth strategy in the aviation, space, and defense markets.
- Project Quantum Leap: This center is part of the company's 'Quantum Leap' initiative aimed at optimizing its global footprint and concentrating resources on high-value, high-margin segments, thereby enhancing overall operational efficiency and market competitiveness.
- Quality and Compliance: The new center will achieve AS9100 certification, ensuring compliance with the most stringent regulatory and quality standards in the aerospace industry, while also planning to pursue Nadcap accreditation to further reinforce customer trust and operational excellence.
- Technology Integration: The facility will consolidate specialized manufacturing, packaging, testing, and quality operations, providing advanced infrastructure and technical expertise to ensure customers achieve consistency and reliability in qualifying new platforms.
See More
